Clinical Trials Directory

Trials / Unknown

UnknownNCT02817308

Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Rambam Health Care Campus · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Ductal adenocarcinoma of the pancreas is the fifth leading cause of cancer related deaths in the European Union. Tumor markers CA19-9 and carcinoembryonic antigen are important components in decision making and follow-up of patients diagnosed with this disease. These tumor markers were found to be elevated not only in the serum but also in other body fluids in patients with malignant lesions of the parotid gland and the urinary tract. The authors have described in a previews small preliminary study a positive and a strong linear correlation between the levels of CA19-9 in urine and saliva with those presented in the serum of patients with ductal adenocarcinoma of the pancreas. The current study seeks to enlarge the study population to confirm the previous results and standardize the measured levels of CA19-9 in these body fluids.

Conditions

Interventions

TypeNameDescription
OTHERsamples of blood, saliva and urineSpot samples of Blood, urine and saliva

Timeline

Start date
2016-07-01
Primary completion
2020-01-01
Completion
2020-01-01
First posted
2016-06-29
Last updated
2018-08-31

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT02817308. Inclusion in this directory is not an endorsement.

Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancrea (NCT02817308) · Clinical Trials Directory